Increased serum type i interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens

Scandinavian Journal of Rheumatology

Volumn 42, Issue 3, 2013, Pages 235-240

  Wuttge, D M ^a   Lood, C ^a,b   Tufvesson, E ^a   Scheja, A ^a   Truedsson, L ^b   Bengtsson, A A ^a   Hesselstrand, R ^a  

^a LUND UNIVERSITY   (Sweden)

^b Department of Laboratory Medicine ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3D; DNA TOPOISOMERASE; IMMUNOGLOBULIN G; INTERFERON; RIBONUCLEOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG FIBROSIS; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 84877884719     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.736532     Document Type: Article

References (14)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010;10:65-73.
3. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther 2010;12(Suppl 1):S1.
4. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36.
5. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010;62:589-98.
6. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
7. Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008;58:2163-73.
8. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396-402.
9. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
10. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
11. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
12. Wuttge DM, Wildt M, Geborek P, Wollheim FA, Scheja A, Akesson A. Serum interleukin-15 (IL-15) in patients with early systemic sclerosis- A potential novel marker of lung disease. Arthritis Res Ther 2007;9: R85.
13. Wuttge DM, Bozovic G, Hesselstrand R, Aronsson D, Bjermer L, Scheja A, et al. Increased alveolar nitric oxide in early systemic sclerosis. Clin Exp Rheumatol 2010;28(Suppl 62): S5-9.
14. Bengtsson AA, Sturfelt G, Lood C, Ronnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of ABR-215757, a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:1579-88.